PLTR
Palantir Technologies Inc.
PLTR has the edge over RCAT overall, supported by stronger valuation and stronger fundamentals.
RCAT
Red Cat Holdings, Inc.
RCAT's outlook is improving, though it still trails on the overall score.
PLTR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
PLTR's revenue, profitability, cash flow and balance sheet are all currently strong.
RCAT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
RCAT's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
PLTR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 75x | $172 | — |
| Current | 120x | $172 | — |
| Cheap | 165x | $236 | +37% |
| Fair | 251x | $359 | +109% |
| Expensive | 452x | $646 | +277% |
Historical ranges are pointers, not guarantees.
PLTR's PE is in its cheap range at 120x. If earnings grow as analysts expect, today's price would be 75x next year's earnings.
RCAT PE Valuation
RCAT has no meaningful PE right now: it lost money over the past year.
PLTR Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Moderate | |
| Moderate |
PLTR has the edge over RCAT on the outlook, with more favorable earnings expectations.
RCAT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect RCAT's revenue to grow and its profitability to improve, with its earnings holding steady.
PLTR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.30 | +61% |
| Q3 2026 | $1.43 | +240% |
| Q2 2026 | $1.17 | +290% |
| Q1 2026 | $0.89 | +287% |
| Q4 2025 | $0.63 | +232% |
| Q3 2025 | $0.42 | +110% |
| Q2 2025 | $0.30 | +76% |
| Q1 2025 | $0.23 | +92% |
| Q4 2024 | $0.19 | +111% |
PLTR has the edge over RCAT on earnings quality, reporting a profit while its opponent remains loss making.
RCAT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.79 | +$0.04 |
| Q1 2026 | -$0.68 | +$0.16 |
| Q1 2023 | -$0.38 | -$0.07 |
| Q4 2022 | -$0.33 | +$0.27 |
| Q3 2022 | -$0.26 | +$0.33 |
| Q2 2022 | -$0.24 | +$0.32 |
RCAT lost $0.79 per share over the past year, about the same as its loss the year before.
PLTR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.3B | +96% |
| Q2 2026 | $1.9B | +93% |
| Q1 2026 | $1.6B | +85% |
| Q4 2025 | $1.4B | +70% |
| Q3 2025 | $1.2B | +63% |
| Q2 2025 | $1B | +48% |
| Q1 2025 | $883.9M | +39% |
| Q4 2024 | $827.5M | +36% |
PLTR's revenue has grown year over year every quarter since late 2020: $2.3B last quarter, up 96% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 47% | +14 points |
| Q2 2026 | 47% | +20 points |
| Q1 2026 | 46% | +26 points |
| Q4 2025 | 41% | +40 points |
| Q3 2025 | 33% | +18 points |
| Q2 2025 | 27% | +11 points |
| Q1 2025 | 20% | +7.2 points |
| Q4 2024 | 1.3% | -9.5 points |
PLTR has the edge over RCAT on profitability, with a higher operating margin.
RCAT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $20.2M | +527% |
| Q1 2026 | $15.5M | +849% |
| Q4 2025 | $26.2M | +1866% |
| Q3 2025 | $9.6M | +529% |
| Q2 2025 | $3.2M | +16% |
| Q1 2025 | $1.6M | -74% |
| Q4 2024 | $1.3M | -77% |
| Q4 2024 | $1.5M | -61% |
RCAT's revenue has grown year over year for five quarters in a row: $20M last quarter, up 527% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -191% | +202 points |
| Q1 2026 | -176% | +589 points |
| Q4 2025 | -91% | +616 points |
| Q3 2025 | -182% | +687 points |
| Q2 2025 | -393% | +54 points |
| Q1 2025 | -766% | -647 points |
| Q4 2024 | -707% | -631 points |
| Q4 2024 | -869% | -753 points |
RCAT's operating margin was −191% last quarter, up 202 points from the same quarter a year ago.
PLTR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.2B | +139% |
| Q2 2026 | $1.2B | +126% |
| Q1 2026 | $891.8M | +193% |
| Q4 2025 | $764M | +67% |
| Q3 2025 | $500.9M | +20% |
| Q2 2025 | $531.6M | +276% |
| Q1 2025 | $304.1M | +140% |
| Q4 2024 | $457.2M | +54% |
PLTR has the edge over RCAT on cash generation, producing positive trailing cash flow while its opponent burns cash.
RCAT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$52.6M | -$39.4M |
| Q1 2026 | -$38.7M | -$22.5M |
| Q4 2025 | -$41.9M | -$25.7M |
| Q3 2025 | -$24.5M | -$14.4M |
| Q2 2025 | -$13.2M | -$10.8M |
| Q1 2025 | -$16.2M | -$13.8M |
| Q4 2024 | -$16.1M | -$12M |
| Q4 2024 | -$10.2M | -$5.7M |
RCAT has burned cash in almost every quarter: −$158M over the past year, against −$56M the year before.
PLTR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +5.2M shares |
| 1 year | +0.1% | +2.9M shares |
| 3 years | +11% | +248M shares |
| 5 years | +31% | +610M shares |
| Available history | +184% | +1.7B shares |
PLTR has the edge over RCAT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $19.2M |
| Q3 2025 | $19.2M |
| Q2 2025 | $18.6M |
| Q1 2025 | $18M |
| Q4 2024 | $18.6M |
| Q3 2024 | $18.9M |
| Q2 2024 | $17.7M |
| Q1 2024 | $9M |
RCAT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +13% | +16M shares |
| 1 year | +50% | +45.6M shares |
| 3 years | +146% | +81.2M shares |
| 5 years | +302% | +103M shares |
| Available history | +709% | +120M shares |
RCAT has 137M diluted shares, up 50% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
PLTR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.1x | Net Cash |
| Q2 2026 | -0.8x | Net Cash |
| Q1 2026 | -1.1x | Net Cash |
| Q4 2025 | -1.0x | Net Cash |
| Q3 2025 | -1.9x | Net Cash |
| Q2 2025 | -1.6x | Net Cash |
| Q1 2025 | -2.3x | Net Cash |
| Q4 2024 | -6.1x | Net Cash |
PLTR has more cash than debt.
RCAT Net Leverage
RCAT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
PLTR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.4 | Neutral |
| Stochastic | 47.4 | Neutral |
PLTR's weekly RSI is 51 (neutral) and its Stochastic is 47 (neutral).
RCAT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.5 | Neutral |
| Stochastic | 7.9 | Oversold |
RCAT's weekly RSI is 32 (neutral) and its Stochastic is 8 (oversold).
PLTR PE vs Technology Sector
| Metric | PLTR | Sector median | Relative |
|---|---|---|---|
| PE | 120x | 28x | 331% above |
| PE % | 1 | 38 | 37 pts below |
PLTR is trading at 120x earnings, a 331% premium to the Technology sector's median of 28x.
RCAT PE vs Technology Sector
RCAT has no meaningful PE right now: it lost money over the past year.
PLTR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $185.8 | 7.6% below |
| 20 week MA | $167.6 | 2.4% above |
| 50 week MA | $157.1 | 9.2% above |
| 100 week MA | $143.8 | 19% above |
| 200 week MA | $83.3 | 106% above |
PLTR has the edge over RCAT on trend strength, trading above more of its moving averages.
RCAT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.07 | 22% below |
| 20 week MA | $7.21 | 45% below |
| 50 week MA | $9.91 | 60% below |
| 100 week MA | $9.20 | 57% below |
| 200 week MA | $5.43 | 27% below |
RCAT is in a downtrend: it's below all five of its weekly moving averages, and 27% below its 200-week average.
PLTR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.20 | $27.8 | +202% |
| 2021 | $27.8 | $18.9 | -32% |
| 2022 | $18.9 | $6.29 | -67% |
| 2023 | $6.29 | $17.2 | +173% |
| 2024 | $17.2 | $79.1 | +361% |
| 2025 | $79.1 | $188.7 | +139% |
| 2026 YTD | $188.7 | $171.6 | -9.1% |
PLTR has the edge over RCAT on returns for 2026, with the stronger performance.
RCAT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.28 | $1.75 | +37% |
| 2021 | $1.75 | $2.18 | +25% |
| 2022 | $2.18 | $0.77 | -65% |
| 2023 | $0.77 | $0.88 | +14% |
| 2024 | $0.88 | $12.3 | +1293% |
| 2025 | $12.3 | $8.30 | -32% |
| 2026 YTD | $8.30 | $3.94 | -53% |
RCAT's yearly returns have swung widely, from +1293% in 2024 to −65% in 2022. It's down 53% so far in 2026.